MET and neoplasm: There was a low percentage of MET amplified cells (6% of cells) at first progression on osimertinib (Fig. 4B, left) concordant with the LAT006_2B MET polysomy PDX (MET amplification in 2% of cells; Fig. 4A, middle) generated from the same patient tumor.